We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Dengue Diagnosis Tested in Urine and Saliva Specimens

By LabMedica International staff writers
Posted on 13 Oct 2015
Dengue is the most important arthropod-borne disease affecting humans, representing a huge public health burden in affected countries. More...
Symptoms are often nonspecific, hence the need for an early, sensitive, and specific diagnosis of dengue for appropriate management.

Direct diagnosis of Dengue virus (DENV) infection is based on virus isolation, detection of the viral genome by reverse transcription polymerase chain reaction (RT-PCR) or detection of nonstructural protein-1 (NS1) antigen. Indirect diagnosis using serological methods to detect anti-DENV immunoglobulin M (IgM) and IgG is

Scientists at the Institut Pasteur du Cambodge (Phnom Penh, Cambodia) collected and analyzed a total, 913 plasma, 1,555 urine and 1,564 saliva samples obtained from 267 patients with confirmed dengue infection and complete records. The clinical specimens obtained from 20 patients hospitalized for a non-dengue febrile illness were also used to assess the specificity of the different diagnostic methods in urine and saliva samples. These controls showed no biological evidence of on-going DENV infection (DENV qRT-PCR negative, NS1 test negative and no anti-DENV antibodies in paired plasma.

A capture enzyme-linked immunosorbent assay (ELISA) was used to detect NS1 in plasma, non-concentrated urine, and undiluted saliva. In plasma and urine, the NS1 protein was detected by the two-step ELISA method. In-house capture ELISAs were used to detect anti-DENV IgM (MAC-ELISA) and IgA (AAC-ELISA) in plasma, non-concentrated urine and undiluted saliva specimens. The viral ribonucleic acid (RNA) was extracted from plasma, saliva mixed with viral transport medium (VTM) and concentrated urine, using the QIAmp Viral RNA Mini kit (Qiagen; Hilden, Germany). Urine samples were concentrated using the 100K Microsep ultrafiltration device (Pall Corporation; Port Washington, NY, USA) to convert an initial volume of 5 mL urine to a final volume of 280 µL of concentrated urine.

The RT-PCR and NS1 tests demonstrated an overall sensitivity of 85.4%/63.4%, 41.6%/14.5%, and 39%/28.3%, in plasma, urine and saliva specimens, respectively. When urine and saliva samples were collected at the same time-points and tested concurrently, the diagnostic sensitivity of RNA and NS1 detection assays was 69.1% and 34.4%, respectively. IgG/IgA detection assays had an overall sensitivity of 54.4%/37.4%, 38.5%/26.8%, and 52.9%/28.6% in plasma, urine, and saliva specimens, respectively. IgM were detected in 38.1% and 36% of the plasma and saliva samples but never in urine.

The authors concludes that although the performance of the different diagnostic methods were not as good in saliva and urine as in plasma specimens, the results obtained by qRT-PCR and by anti-DENV antibody ELISA could well justify the use of these two body fluids to detect dengue infection in situations when the collection of blood specimens is not possible. The study was published on September 25, 2015, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:

Institut Pasteur du Cambodge 
Qiagen 
Pall Corporation 



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.